| 摘要 |
<p>The present invention is directed to methods to rapidly assess the overall coagulant properties of a patient's blood sample by measuring and comparing clotting time with and without an added inhibitor of a procoagulant or an anticoagulant. When the sample is whole blood, the resulting clotting time represents the overall coagulant activity of the plasma and cellular components of the blood, which is indicative of existing or impending pathology arising from abnormal coagulability. The invention also provides a method for measuring the risk of a patient for a thrombotic event by determining functionally current levels of one or more procoagulants or anticoagulants in whole blood. In addition, a method for measuring the effectiveness of anticoagulant therapy is provided. Kits for performing the method of the invention are also provided.</p> |
